An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)
NCT ID: NCT01394276
Last Updated: 2025-09-11
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
322 participants
OBSERVATIONAL
2011-05-31
2013-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
NCT01543503
An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice
NCT01474291
An Observational Study of RoActemra/Actemra in Patients With Moderate to Severe Rheumatoid Arthritis
NCT01375478
An Observational Study of Glucocorticoid Use in Patients With Rheumatoid Arthritis on Treatment With RoActemra/Actemra (Tocilizumab)
NCT01392001
An Observational Study of RoActemra/Actemra (Tocilizumab) in Rheumatoid Arthritis Patients
NCT01615419
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tocilizumab
Participants with moderate to severe Rheumatoid arthritis (RA) who had received RoActemra \[Tocilizumab (TCZ)\] treatment for 6 months prior to initiation of study and are inadequate responders to Disease Modifying Anti-Rheumatic Drugs (DMARDs) and anti-Tumor Necrosis Factors (anti-TNFs) agents were observed. Participants received treatment with TCZ with dose of 8 milligrams per kilogram (mg/kg) body weight, intravenously once every 4 weeks for 12 months according to European Union (EU) approved dosage, and Summary of Product Characteristics (SmPC).
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Rheumatoid arthritis diagnosed according to American College of Rheumatology (ACR) criteria
* Initiated on RoActemra/Actemra treatment according to the Summary of Product Characteristics not more than 6 months before opening of study center
Exclusion Criteria
* Hypersensitivity to the active component or any of the excipients
* Pregnant women
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Coppito, Abruzzo, Italy
Pescara, Abruzzo, Italy
Brindisi, Apulia, Italy
Casarano (LE), Apulia, Italy
Foggia, Apulia, Italy
Martina Franca, Apulia, Italy
San Cesario di Lecce, Apulia, Italy
Reggio Calabria, Calabria, Italy
Avellino, Campania, Italy
Gragnano, Campania, Italy
Napoli, Campania, Italy
Napoli, Campania, Italy
Napoli, Campania, Italy
Salerno, Campania, Italy
Telese Terme, Campania, Italy
Bologna, Emilia-Romagna, Italy
Ferrara, Emilia-Romagna, Italy
Modena, Emilia-Romagna, Italy
Piacenza, Emilia-Romagna, Italy
Trieste, Friuli Venezia Giulia, Italy
Albano Laziale, Lazio, Italy
Rome, Lazio, Italy
Rome, Lazio, Italy
Rome, Lazio, Italy
Rome, Lazio, Italy
Rome, Lazio, Italy
Viterbo, Lazio, Italy
Arenzano, Liguria, Italy
Castel Goffredo, Lombardy, Italy
Gavardo, Lombardy, Italy
Legnano, Lombardy, Italy
Milan, Lombardy, Italy
Monza, Lombardy, Italy
Pavia, Lombardy, Italy
Rozzano, Lombardy, Italy
Saronno, Lombardy, Italy
Treviglio, Lombardy, Italy
Vimercate, Lombardy, Italy
Agnone, Molise, Italy
Cuneo, Piedmont, Italy
Novara, Piedmont, Italy
Turin, Piedmont, Italy
Sassari, Sardinia, Italy
Catania, Sicily, Italy
Gazzi, Sicily, Italy
Palermo, Sicily, Italy
Palermo, Sicily, Italy
Ancona, The Marches, Italy
Iesi, The Marches, Italy
Florence, Tuscany, Italy
Massa, Tuscany, Italy
Pisa, Tuscany, Italy
Prato, Tuscany, Italy
Perugia, Umbria, Italy
Verona, Veneto, Italy
Verona, Veneto, Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML25728
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.